Alumis Promotes Sanam Pangali to Chief Legal Officer-February 2024-www.financetom.com

Alumis Promotes Sanam Pangali to Chief Legal Officer

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Alumis Promotes Sanam Pangali to Chief Legal Officer

Jul 14, 2025 2:10 PM

04:33 PM EDT, 07/14/2025 (MT Newswires) -- Alumis ( ALMS ) promoted Sanam Pangali to chief legal officer.

Pangali, who most recently served as senior vice president of legal, succeeds Sara Klein, who retired, Alumis ( ALMS ) said Monday in a statement.

Previous page： Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition Next page： Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition

Aug 12, 2024

03:45 PM EDT, 08/12/2024 (MT Newswires) -- (Updates to reflect Eli Lilly ( LLY ) declined comment to MT Newswires) Eli Lilly ( LLY ) filed a prospectus Monday to raise debt for its $3.2 billion acquisition of Morphic. According to a securities filing, the pharma company is looking to issue five separate series of notes to raise $5 billion...

Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss

Aug 12, 2024

03:45 PM EDT, 08/12/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) shares were down nearly 8% in recent Monday trading after the company reported a wider-than-expected Q2 net loss. The company reported a Q2 net loss of $0.33 per diluted share, compared with a loss of $0.46 a year earlier. Analysts polled by Capital IQ expected a $0.18 loss....

Novartis loses initial bid to block generic of best-selling heart drug

Aug 12, 2024

Aug 12 (Reuters) - Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday. U.S. District Judge Richard Andrews ruled that Novartis' chance of winning its patent-infringement lawsuit challenging the generic was too low to justify halting...

Portillo's Insider Sold Shares Worth $679,675, According to a Recent SEC Filing

Aug 12, 2024

03:56 PM EDT, 08/12/2024 (MT Newswires) -- Michael Osanloo, Director, President & CEO, on August 09, 2024, sold 66,052 shares in Portillo's (PTLO) for $679,675. Following the Form 4 filing with the SEC, Osanloo has control over a total of 79,041 shares of the company, with 79,041 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1871509/000187150924000105/xslF345X03/wk-form4_1723492418.xml Price: 10.82, Change: +0.11, Percent Change: +1.03...